HBOT for concussion, brain injury, and PTSD: evidence and risks

Concussion and PTSD need separate evidence

HBOT is not established routine care for persistent concussion symptoms. The 2021 VA/DoD guideline recommends against it for symptoms attributed to mild traumatic brain injury (TBI). For PTSD, the 2023 guideline found too little evidence to recommend for or against HBOT; a later small trial reported benefit. These are different diagnoses and evidence questions.

Before considering a brain-health package, ask which diagnosis each part is intended to address. Persistent symptoms after mild TBI, a recent severe brain injury, PTSD, and age-related memory concerns have different treatment needs. A program combining scans, oxygen, and rehabilitation should explain the evidence for each component and how progress will be assessed.

Persistent concussion: encouraging no-treatment comparisons

A 2013 randomized study in which groups received treatment at different times assessed 56 people with persistent symptoms years after mild TBI. It reported cognitive and quality-of-life gains after HBOT compared with a waiting period. A 2020 randomized study in which groups received treatment at different times enrolled 63 civilian and military participants, with 50 completing primary outcome testing, and also reported improvements compared with no treatment. These studies explain why researchers and patients remain interested. Neither included a chamber sham that matched the treatment experience.

Waiting-period comparisons can help describe change over time, but participants know when they are receiving an intensive intervention. That difference can affect symptom reporting, effort on tests, and concurrent behavior. Repeated assessments and missing outcome data also deserve attention. The appropriate interpretation is that these studies found promising signals under their designs. Stronger claims about oxygen-specific benefit, permanent brain repair, or predictable response require evidence that directly addresses those alternative explanations.

Results from sham-controlled trials

The HOPPS trial randomized 72 military participants among HBOT, pressurized-air sham, and usual care. The chamber groups improved without a clear HBOT advantage over sham. Another trial reported by Wolf and colleagues found no overall difference in cognitive or PTSD composite outcomes among 50 randomized participants completing oxygen or sham exposure. Favorable exploratory subgroups were reported, but a subgroup selected after looking at results is a research lead, not a validated patient-selection rule.

The contrast between sham and waiting controls matters. If both chamber groups improve, attention, expectation, the structured care experience, or a physiological effect of the comparison may contribute. The result cannot specify their relative contributions by itself. It also cannot establish that oxygen adds meaningful benefit. Claims based on military participants should acknowledge that civilian injuries, symptom patterns, and accompanying care may differ. Differences between studies call for better trials instead of selective quotation.

Guidelines and VA coverage

The 2021 VA/DoD guideline strongly recommends against HBOT for symptoms attributed to mild TBI. If a clinic says a newer approach changes that recommendation, ask for the comparative study and how its participants and outcomes match your situation. A positive testimonial cannot answer that question.

The recommendation does not mean that no patient has ever improved or that researchers should abandon all oxygen-related questions. It states how the reviewed evidence supports clinical care for the specified population. An intervention can remain investigational while some studies report favorable changes. Symptom-focused evaluation is still important because sleep, headache, vestibular problems, mental health, and other contributors may need separate attention. Brain-health marketing should make room for that clinical complexity instead of promising a single repair mechanism.

VA Community Care Clinical Determination and Indication 00075, effective and last reviewed July 1, 2026, with its webpage updated August 25, 2026, classifies HBOT for PTSD and TBI as investigational and experimental and not covered under that determination. This is a dated VA coverage policy, separate from the clinical guideline positions: the 2021 mild-TBI guideline recommends against HBOT for attributed symptoms, while the 2023 PTSD guideline finds insufficient evidence to recommend for or against. Coverage from another payer or a research program requires its own verification.

Severe TBI research is a separate question

The HOBIT study, NCT02407028, addresses severe traumatic brain injury and is described by the SIREN research network as an adaptive trial to select treatment parameters before a definitive efficacy study. It concerns a different setting from commercial outpatient treatment for persistent concussion symptoms. Its design reflects questions about outcomes and complications in severely injured patients. A trial exists because important uncertainty remains; its existence does not establish a benefit for another population.

When a clinic cites severe-TBI research, ask whether the injury severity, time since injury, surrounding medical care, and measured outcome match its service. A biological observation in acute injury cannot be assumed to apply years later. A registered trial also needs a published outcome report before it can be cited as positive evidence. Recruitment status can change, so a trial-record link is a starting point for verification rather than a guarantee that a person can enroll.

PTSD: a newer positive trial with narrow applicability

A 2024 randomized sham-controlled trial enrolled 63 male combat veterans aged 25–60; 56 completed the protocol. It reported benefit on the Clinician-Administered PTSD Scale, with brain-network connectivity explored alongside clinical changes. Participants with a history of TBI were excluded. This makes it a relevant PTSD signal but prevents describing it as proof for combined PTSD and concussion, for every trauma history, or for all ages and genders.

The 2023 VA/DoD PTSD guideline judged HBOT evidence insufficient to recommend for or against. That guideline was published before the newer trial. A small later positive result can change the research conversation without automatically establishing routine treatment or replacing existing PTSD care. Independent replication, broader enrollment, longer follow-up, and careful reporting of adverse events would make the evidence more informative. The trial record is NCT04518007; registration itself is not a clinical endorsement.

Scans, packages, and claims of brain repair

Perfusion scans and functional connectivity measurements can examine physiological changes. They are not interchangeable with a person returning to work, feeling well, or maintaining independence. An association between imaging and symptom change can be scientifically interesting while leaving causation and durability unresolved. Descriptions such as neuroplasticity, regeneration, or brain repair should be evaluated against the actual measurement. A colorful before-and-after image does not demonstrate that the advertised program produces a clinically meaningful benefit.

A written brain-health treatment plan should identify the diagnosis, the evidence status, the outcomes it tracks, and how it responds if improvement does not occur. It should explain who interprets tests, how concurrent treatment is coordinated, and whether its claims rely on its own commercial research. Device clearance and professional credentials answer different questions from effectiveness. FDA safety guidance emphasizes training, monitoring, maintenance, and fire prevention; those safeguards remain relevant when the indication is experimental.

• Ask for comparative evidence for your specific condition.
• Ask whether the advertised response rate includes everyone who started treatment.
• Separate scan changes from meaningful symptoms and daily function.
• Ask how existing care, adverse events, and costs are handled.

Questions to ask

• Does the cited trial involve persistent mild TBI, acute severe TBI, or PTSD without TBI?
• Was a response subgroup prespecified or identified after the trial?
• Does the clinic describe guideline recommendations alongside positive studies?
• Which outcome will show whether the program helped in everyday life?

Sources